We are live on ! Find out more
SGNT

SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT

Delisted

SGNT was delisted on the 29th of August, 2016.

Back to rankings

103 hedge funds and large institutions have $436M invested in SAGENT PHARMACEUTICALS INC COM STK (DE) in 2013 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 43 increasing their positions, 20 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,550% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 2

115% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 20

43% more funds holding

Funds holding: 72 → 103 (+31)

26% more capital invested

Capital invested by funds: $345M → $436M (+$91.1M)

Holders
103
Holders Change
+31
Holders Change %
+43.06%
% of All Funds
3.34%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
33
Increased
43
Reduced
20
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Franklin Resources
Franklin Resources
California
+$87.9M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$8.69M
3
Millennium Management
Millennium Management
New York
+$7.16M
4
PCP
Perimeter Capital Partners
Georgia
+$5.54M
5
OAM
Oxford Asset Management
United Kingdom
+$5.07M

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$23.8M
2
VAM
Visium Asset Management
New York
-$11.3M
3
Morgan Stanley
Morgan Stanley
New York
-$9.34M
4
Federated Hermes
Federated Hermes
Pennsylvania
-$7.95M
5
CS
Credit Suisse
Switzerland
-$7.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
26
Geode Capital Management
Massachusetts
$2.42M +$1.35M +60,851 +105%
BA
27
BlackRock Advisors
Delaware
$2.33M +$662K +29,750 +35%
TCM
28
Timpani Capital Management
Wisconsin
$2.25M +$2.45M +110,215 New
Bank of New York Mellon
29
Bank of New York Mellon
New York
$2.09M +$52.7K +2,368 +2%
WMSA
30
Weiss Multi-Strategy Advisers
New York
$2.06M +$1.14M +51,000 +102%
WC
31
Wexford Capital
Florida
$1.96M +$2.13M +95,890 New
D.E. Shaw & Co
32
D.E. Shaw & Co
New York
$1.95M +$2.13M +95,669 New
CII
33
CR Intrinsic Investors
Connecticut
$1.91M -$1.15M -51,473 -35%
DCM
34
Dupont Capital Management
Delaware
$1.83M +$2M +89,873 New
HCM
35
Highbridge Capital Management
New York
$1.55M +$1.69M +76,007 New
CCMH
36
Cornerstone Capital Management Holdings
New York
$1.52M +$541K +24,300 +48%
HVC
37
Healthcare Value Capital
New Jersey
$1.51M -$648K -29,100 -28%
Jacobs Levy Equity Management
38
Jacobs Levy Equity Management
New Jersey
$1.49M +$1.63M +73,161 New
BC
39
Broadfin Capital
New York
$1.39M +$1.52M +68,300 New
TCIM
40
TIAA CREF Investment Management
New York
$1.35M -$9.08K -408 -0.6%
Dimensional Fund Advisors
41
Dimensional Fund Advisors
Texas
$1.33M +$1.45M +65,111 New
RI
42
Redwood Investments
Massachusetts
$1.3M +$1.42M +63,868 New
Invesco
43
Invesco
Georgia
$1.28M +$1.29M +57,844 +1,180%
PP
44
PDT Partners
New York
$1.27M +$1.38M +62,049 New
Renaissance Technologies
45
Renaissance Technologies
New York
$1.16M +$1.03M +46,400 +455%
Arrowstreet Capital
46
Arrowstreet Capital
Massachusetts
$1.1M +$1.2M +54,080 New
QBFM
47
QS Batterymarch Financial Management
New York
$1.09M +$1.19M +53,300 New
BIM
48
BlackRock Investment Management
Delaware
$1.04M +$180K +8,063 +19%
RFC
49
Russell Frank Company
Washington
$1.04M +$280K +12,562 +33%
CCM
50
Cadence Capital Management
Massachusetts
$995K -$223K -10,013 -17%
1
2
3 4 5

SGNT Hedge Fund Activity: Q3 2013 in Review

103 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) for Q3 2013, worth a combined $436M — up 26% from $345M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new SGNT positions and 2 closed out — a net gain of 31 holders — while 43 added to existing stakes and 20 trimmed.

The largest buyer was Franklin Resources, opening a new position worth an estimated $87.9M. The largest seller was Deerfield Management, cutting an estimated $23.8M.

  • 103 institutional investors held SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) as of Q3 2013, up from 72 in Q2 2013.
  • Funds reported $436M of SAGENT PHARMACEUTICALS INC COM STK (DE) stock for Q3 2013, up 26% quarter-over-quarter.
  • 33 funds opened new SAGENT PHARMACEUTICALS INC COM STK (DE) positions in Q3 2013 and 2 closed out, a net change of +31 holders.
  • The largest SAGENT PHARMACEUTICALS INC COM STK (DE) buyer in Q3 2013 was Franklin Resources, an estimated $87.9M added.
  • The largest SAGENT PHARMACEUTICALS INC COM STK (DE) seller in Q3 2013 was Deerfield Management, an estimated $23.8M sold.

Based on aggregated 13F filings for Q3 2013.